Wedbush raises Tango Therapeutics stock price target on trial data
Wedbush raised Tango Therapeutics' (TNGX) price target to $45 from $39, citing positive trial data for vopimetostat in combination with RayzeBio's inhibitors. The stock has surged 271% over the past year, trading at $24.21 with a $4.06B market cap. Analysts see potential upside of 61% to their consensus target. Other analysts have also raised targets, with H.C. Wainwright at $68 and Stifel at $55.
How this was made
The 30-second read
Why it matters
The strong response rates and lack of dose‑limiting toxicities have prompted several analysts to raise price targets, suggesting a re‑rating of the stock's risk‑reward profile.
Market read
Analyst upgrades driven by new trial data could trigger buying interest and short‑term price appreciation for TNGX.
What to watch
Potential regulatory hurdles and competition from other epigenetic drug developers could limit market share.
Background
Tango Therapeutics (NASDAQ:TNGX) is a clinical‑stage biotech focused on epigenetic therapies for cancer. The company presented Phase 1/2 data at the ESMO 2026 conference.
Ticker impact
Wedbush raised its price target on Tango Therapeutics to $45 after presenting updated Phase 1/2 trial data at ESMO 2026, showing high response rates in pancreatic and lung cancer patients.
likely upward pressure as the market prices in the positive trial data and higher price targets.
Multiple analysts raised targets (Wedbush to $45, H.C. Wainwright to $68, Stifel to $55) following the same data, indicating consensus bullish view.
Market effects
Positive early data may lift sentiment across biotech firms developing epigenetic therapies for solid tumors.
US biotech sector could see modest gains as investors rotate into high‑growth pipeline stocks.
Trial data could attract international investors seeking exposure to innovative oncology treatments.
Counterpoint
The data are early‑stage and based on small patient cohorts; efficacy may not translate to later‑stage trials, posing downside risk.
Key entities
- AnalystWedbush
Raised price target to $45, Outperform rating.
- AnalystH.C. Wainwright
Raised price target to $68, Buy rating.
- AnalystStifel
Raised price target to $55, Buy rating.
